Treatment of a patient with Parkinson’s Disease using stem cell therapy – Video
By Dr. Matthew Watson
Treatment of a patient with Parkinson #39;s Disease using stem cell therapy
Here we demonstrate how a patient who suffers from Parkinson #39;s Disease has benefited from stem cell therapy with us in Panama.
By: SCRMPanama
Read the rest here:
Treatment of a patient with Parkinson's Disease using stem cell therapy - Video
Uncategorized
Comments Off on Treatment of a patient with Parkinson’s Disease using stem cell therapy – Video |
May 19th, 2013
Ellen Jorgensen is dragging genetic engineering away from the scare stories – Wired.co.uk
By Dr. Matthew Watson
Ellen Jorgensen is dragging genetic engineering away from the scare stories Wired.co.uk Biohackers are rare -- costs have kept genetic engineering in the realm of big pharma and university labs. But Ellen Jorgensen, a PhD molecular biologist, sees a tipping point: "You can sequence genes on a computer, email them to a lab and a week later ... |
Uncategorized
Comments Off on Ellen Jorgensen is dragging genetic engineering away from the scare stories – Wired.co.uk |
May 19th, 2013
Progenics Pharmaceuticals Added to the NASDAQ Biotechnology Index – NASDAQ
By Dr. Matthew Watson
Progenics Pharmaceuticals Added to the NASDAQ Biotechnology Index NASDAQ The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ Stock Market-listed securities classified according to the Industry Classification Benchmark (ICB) as either Biotechnology or Pharmaceuticals. The NASDAQ ... NASDAQ Biotechnology Index surpasses all-time high in 1Q13Lexology (registration) |
Uncategorized
Comments Off on Progenics Pharmaceuticals Added to the NASDAQ Biotechnology Index – NASDAQ |
May 19th, 2013
State to market growing biotechnology industry – al.com
By Dr. Matthew Watson
State to market growing biotechnology industry al.com BIRMINGHAM, Alabama – Alabama's burgeoning biotech industry, with about 550 companies statewide, has to a degree escaped the notice of the world, Alabama Secretary of Commerce Greg Canfield said today. The state intends to change that. |
Uncategorized
Comments Off on State to market growing biotechnology industry – al.com |
May 19th, 2013
Teachers become the students at biotechnology symposium – Medill Reports: Chicago
By Dr. Matthew Watson
 Medill Reports: Chicago | Teachers become the students at biotechnology symposium Medill Reports: Chicago Chicago area high school students will spend less time at their desks next fall after their science teachers attended the second annual Biotechnology Symposium Tuesday at Northwestern University. The conference and upcoming summer development series ... |
Uncategorized
Comments Off on Teachers become the students at biotechnology symposium – Medill Reports: Chicago |
May 19th, 2013
NewLink Genetics to Be Added to NASDAQ Biotechnology Index – Marketwire – Marketwire (press release)
By Dr. Matthew Watson
NewLink Genetics to Be Added to NASDAQ Biotechnology Index - Marketwire Marketwire (press release) The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities classified according to the Industry Classification Benchmark (ICB) as either Biotechnology or Pharmaceuticals. These companies must meet ... |
Uncategorized
Comments Off on NewLink Genetics to Be Added to NASDAQ Biotechnology Index – Marketwire – Marketwire (press release) |
May 19th, 2013
Clinical testing of Singapore’s first influenza vaccine starts – Channel News Asia
By Dr. Matthew Watson
 Channel News Asia | Clinical testing of Singapore's first influenza vaccine starts Channel News Asia Singapore's first healthy volunteer has been given a dose of the H1N1 influenza vaccine developed by Singapore's A*STAR and Switzerland's Cytos Biotechnology AG in a clinical trial. PHOTOS. A medical technician performs tests for viruses (AFP) ... First influenza vaccine brought to clinical testing - Medical XpressMedical Xpress Singapore's first H1N1 flu vaccine starts clinical testXinhua A*Star and Cytos advance Singapore's first flu vaccinePharmaTimes |
Uncategorized
Comments Off on Clinical testing of Singapore’s first influenza vaccine starts – Channel News Asia |
May 19th, 2013
Sony Biotechnology Inc.’s New Technology for Science Provides Researchers … – PR Newswire (press release)
By Dr. Matthew Watson
Sony Biotechnology Inc.'s New Technology for Science Provides Researchers ... PR Newswire (press release) CHAMPAIGN, Ill., May 17, 2013 /PRNewswire/ -- Sony Biotechnology Inc. ("Sony") today announced the launch of the new Sony SP6800 Spectral Analyzer (SP6800). Sony will be exhibiting and taking orders for this system at CYTO 2013, which will be held at ... Sony Delivers New Technology for Science to CYTO 2013International Business Times (press release) |
Uncategorized
Comments Off on Sony Biotechnology Inc.’s New Technology for Science Provides Researchers … – PR Newswire (press release) |
May 19th, 2013
Bowman decision affirms future of seed biotechnology – Delta Farm Press
By Dr. Matthew Watson
Daily Beast | Bowman decision affirms future of seed biotechnology Delta Farm Press The TheTThe The???? In a 9-0 ruling, the Supreme Court rejected soybean farmer Vernon Bowman's claim that he was within his rights to plant Monsanto's Roundup Ready soybeans without the company's approval. The decision upholds Monsanto's seed ... Supreme Court unanimously upholds patent-holders rights in agricultural ...Lexology (registration) Supreme Court Holds That Exhaustion Doctrine Does Not Permit Purchasers Of ...Mondaq News Alerts (registration) Supreme Court Sides with Monsanto on Issue of Patent Protection for ...The National Law Review agprofessional.com all 50 news articles » |
Uncategorized
Comments Off on Bowman decision affirms future of seed biotechnology – Delta Farm Press |
May 19th, 2013
PUMA BIOTECHNOLOGY INC : Puma Biotechnology Comment on Trading Activity – 4-traders (press release)
By Dr. Matthew Watson
PUMA BIOTECHNOLOGY INC : Puma Biotechnology Comment on Trading Activity 4-traders (press release) Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, has been contacted by the New York Stock Exchange regarding today's trading in the Company's common stock. It is the Company's policy not to comment on trading ... Puma Biotech Gains After Rival Drug Data Show No ThreatBloomberg |
Uncategorized
Comments Off on PUMA BIOTECHNOLOGY INC : Puma Biotechnology Comment on Trading Activity – 4-traders (press release) |
May 19th, 2013
Sanford Research Team Discovers Promising Batten Disease Therapy – PRWeb – PR Web (press release)
By Dr. Matthew Watson
 PR Web (press release) | Sanford Research Team Discovers Promising Batten Disease Therapy - PRWeb PR Web (press release) A team from Sanford Research has discovered a potentially promising therapy for reducing the degenerative effects of Batten disease, according to a recent study published by Human Molecular Genetics. Sanford Research's Jake Miller, Chun-Hung Chan, ... |
Uncategorized
Comments Off on Sanford Research Team Discovers Promising Batten Disease Therapy – PRWeb – PR Web (press release) |
May 19th, 2013
Term Limits: Eugenie C. Scott and the Retirement of "Darwinism" – Discovery Institute
By Dr. Matthew Watson
Discovery Institute | Term Limits: Eugenie C. Scott and the Retirement of "Darwinism" Discovery Institute Dragutin Savic is professor of Molecular Genetics at the Faculty of Sciences, University of Belgrade. He spent several years as a visiting scientist at Johns Hopkins University, Carolinska Institute and Institute J. Monod. This article considers ... |
Uncategorized
Comments Off on Term Limits: Eugenie C. Scott and the Retirement of "Darwinism" – Discovery Institute |
May 19th, 2013
Sisters increase awareness of hereditary breast cancer – Richmond Times Dispatch
By Dr. Matthew Watson
Sisters increase awareness of hereditary breast cancer Richmond Times Dispatch “As much as we try to be science-based, there's not a real clear algorithm that says this is the path you should take,” said John Quillin, an assistant professor of human and molecular genetics at VCU Massey Cancer Center and a genetic counselor in the ... |
Uncategorized
Comments Off on Sisters increase awareness of hereditary breast cancer – Richmond Times Dispatch |
May 19th, 2013
Pennington Biomedical Research Center, LSU to honor Dr. Jeffery Friedman – NOLA.com
By Dr. Matthew Watson
Pennington Biomedical Research Center, LSU to honor Dr. Jeffery Friedman NOLA.com Friedman, a Marilyn M. Simpson Professor at The Rockefeller University and investigator at Howard Hughes Medical Institute, was nominated for his scientific achievement in the field of molecular genetics, and for his discovery of leptin, a hormone that ... |
Uncategorized
Comments Off on Pennington Biomedical Research Center, LSU to honor Dr. Jeffery Friedman – NOLA.com |
May 19th, 2013
plant throws out ‘junk’ DNA – University at Buffalo Reporter
By Dr. Matthew Watson
University at Buffalo Reporter | plant throws out 'junk' DNA University at Buffalo Reporter ... State University; Nanyang Technological University; Centre for Genomic Regulation in Barcelona; Universitat Pompeu Fabra; Max Planck Institute for Molecular Genetics; Indiana University; Rutgers University; and the Donald Danforth Plant Science Center. |
Uncategorized
Comments Off on plant throws out ‘junk’ DNA – University at Buffalo Reporter |
May 19th, 2013
Technion professor to lecture here on ‘Genetics of Being Jewish’ – St. Louis Jewish Light
By Dr. Matthew Watson
Technion professor to lecture here on 'Genetics of Being Jewish' St. Louis Jewish Light He now conducts research in human molecular genetics and stem cell biology. Skorecki's interest in population genetics began with a series of research studies tracing patrilineal genealogies in the Jewish priesthood and shared ancestries of Diaspora ... |
Uncategorized
Comments Off on Technion professor to lecture here on ‘Genetics of Being Jewish’ – St. Louis Jewish Light |
May 19th, 2013
Replicating Oregon Cloning in California: Views on the Legality
By Dr. Matthew Watson
Oregon's stem cell cloning achievement
has triggered some discussion about whether it could be replicated
legally in California, which bans paying for eggs as was done in
Oregon.
Stanford researcher Irv Weissman said
it is “not true” that Oregon's stem cell research would be
illegal in California. Leftovers from IVF clinics could be used, he said.
it is “not true” that Oregon's stem cell research would be
illegal in California. Leftovers from IVF clinics could be used, he said.
But in response Oregon researcher
Shoukhrat Mitalipov said that “SCNT (the process he used) did not
work with discarded human eggs.”
Shoukhrat Mitalipov said that “SCNT (the process he used) did not
work with discarded human eggs.”
He added,
“SCNT worked with eggs from
healthy young volunteers (paid of course). IVF patients (whether paid
or not) have reproductive health problems and may not provide
acceptable quality eggs for SCNT.”
Their comments came in emails to the
California Stem Cell Report in connection with yesterday's item that said because the Oregon researchers used paid donors for eggs, the research would be illegal in the Golden State.
California Stem Cell Report in connection with yesterday's item that said because the Oregon researchers used paid donors for eggs, the research would be illegal in the Golden State.
Weissman said,
"Not true. They did
it with nearly 40 percent efficiency, which does not require paying
for eggs, just use leftovers from IVF clinics."
There is no question that it is illegal
to pay donors for their eggs in California. The question is whether
the research could be done properly without using paid donors. In recent
years, researchers at Harvard and elsewhere have said they needed paid donors for stem cell research to properly perform their research
and could not find them without providing compensation.
to pay donors for their eggs in California. The question is whether
the research could be done properly without using paid donors. In recent
years, researchers at Harvard and elsewhere have said they needed paid donors for stem cell research to properly perform their research
and could not find them without providing compensation.
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/IimgOYxndkg/replicating-oregon-cloning-in.html
Stem Cell Therapy
Comments Off on Replicating Oregon Cloning in California: Views on the Legality |
May 19th, 2013
Weissman Says Oregon-style Stem Cell Research Could be Done in California
By Dr. Matthew Watson
Stanford researcher Irv Weissman says it
is “not true” that Oregon's stem cell research could not be done
legally in California.
In a brief email to the California Stem
Cell Report, he commented in connection with yesterday's item that said because the Oregon researchers used paid donors for eggs,the research would be illegal in the Golden State.
Cell Report, he commented in connection with yesterday's item that said because the Oregon researchers used paid donors for eggs,the research would be illegal in the Golden State.
Weissman said,
"Not true. They did
it with nearly 40 percent efficiency, which does not require paying
for eggs, just use leftovers from IVF clinics."
There is no question that it is illegal
to pay donors for their eggs in California. The question is whether
the research could be done without using paid donors. In recent
years, researchers at Harvard and elsewhere have said they needed paid donors to properly perform their research
and could not find them without providing compensation.
to pay donors for their eggs in California. The question is whether
the research could be done without using paid donors. In recent
years, researchers at Harvard and elsewhere have said they needed paid donors to properly perform their research
and could not find them without providing compensation.
We have queried Shoukhrat Mitalipov in
Oregon concerning his views on Weissman's comments. We welcome other
comments as well. Comments can be filed directly by clicking on the word "comment" at the end of this item or you can email them to djensen@californiastemcellreport.com.
Oregon concerning his views on Weissman's comments. We welcome other
comments as well. Comments can be filed directly by clicking on the word "comment" at the end of this item or you can email them to djensen@californiastemcellreport.com.
We should also note the comment from
researcher Paul Knoepfler of UC Davis who notes that SCNT cloning is
permissible in California, which is what was done in Oregon. The
state does ban reproductive cloning, however.
researcher Paul Knoepfler of UC Davis who notes that SCNT cloning is
permissible in California, which is what was done in Oregon. The
state does ban reproductive cloning, however.
Source:Stem Cell Therapy
Comments Off on Weissman Says Oregon-style Stem Cell Research Could be Done in California |
May 19th, 2013
Oregon-style Stem Cell Cloning Research Illegal in California: No Pay for Eggs in Golden State
By Dr. Matthew Watson
The good news out of Oregon is that
some diligent scientists in the Beaver State have accomplished a
major advance in stem cell research --- the cloning of human stem
cells.
That bad news is that their research
would have been illegal in California, and probably will be banned
for decades, if not longer – thanks to Proposition 71 of 2004.
would have been illegal in California, and probably will be banned
for decades, if not longer – thanks to Proposition 71 of 2004.
The proposition was the ballot
initiative that created the $3 billion California stem cell agency,
which is hailed internationally as being one of the world leaders in
financing stem cell science. Unfortunately, the 10,000-word
initiative also contains language that was aimed at winning voter
approval of the measure -- not promoting good science.
initiative that created the $3 billion California stem cell agency,
which is hailed internationally as being one of the world leaders in
financing stem cell science. Unfortunately, the 10,000-word
initiative also contains language that was aimed at winning voter
approval of the measure -- not promoting good science.
The team writing the initiative, led by
Robert Klein, the former and first chairman of the stem cell agency,
put in a provision that made it illegal to pay women for their eggs.
The Oregon researchers paid women $3,000 to $7,000 each for their eggs, reflecting the current market rate based on prices paid in
connection with IVF. In some cases for IVF, the compensation is
dramatically higher. (See here and here.) Stem cell researchers in
recent years in the United States have found that they cannot secure
an adequate number of donors without matching IVF donor compensation.
Robert Klein, the former and first chairman of the stem cell agency,
put in a provision that made it illegal to pay women for their eggs.
The Oregon researchers paid women $3,000 to $7,000 each for their eggs, reflecting the current market rate based on prices paid in
connection with IVF. In some cases for IVF, the compensation is
dramatically higher. (See here and here.) Stem cell researchers in
recent years in the United States have found that they cannot secure
an adequate number of donors without matching IVF donor compensation.
While compensation for eggs is a matter
of some controversy, strong cases have been made that women
should make their own decisions about selling their eggs – not the what some call the nanny state. Of course, that should occur under well-regulated
situations. But Proposition 71 backers wanted to remove any possible
campaign objections by opponents of stem cell research, and so they
inserted the ban along with management minutia and other dubious
material.
of some controversy, strong cases have been made that women
should make their own decisions about selling their eggs – not the what some call the nanny state. Of course, that should occur under well-regulated
situations. But Proposition 71 backers wanted to remove any possible
campaign objections by opponents of stem cell research, and so they
inserted the ban along with management minutia and other dubious
material.
Can't that be changed, one might ask?
Not without a herculean effort. That means another ballot measure or
a super, super majority vote in the California legislature plus the
signature of the governor. Imagine a measure on the ballot to
allow women to sell their eggs. The uproar would be heard
internationally. In 2004, when Proposition 71 was approved, it would
have been better to leave the compensation issue unaddressed. Then it
could have been dealt with through regulation or normal legislation,
both of which are far more flexible than ballot measures that alter
the state Constitution and state law.
Not without a herculean effort. That means another ballot measure or
a super, super majority vote in the California legislature plus the
signature of the governor. Imagine a measure on the ballot to
allow women to sell their eggs. The uproar would be heard
internationally. In 2004, when Proposition 71 was approved, it would
have been better to leave the compensation issue unaddressed. Then it
could have been dealt with through regulation or normal legislation,
both of which are far more flexible than ballot measures that alter
the state Constitution and state law.
Our quick and limited survey of the
news coverage indicated that many of the mainstream media stories
omitted the price of the eggs, which may suggest that the issue of
compensation is becoming moot.
news coverage indicated that many of the mainstream media stories
omitted the price of the eggs, which may suggest that the issue of
compensation is becoming moot.
In related news about the Oregon
accomplishment, UC Davis stem cell researcher Paul Knoepfler has
posted a good look at the some of the misinformation that is
surfacing on the Internet about the research, including its
implications.
accomplishment, UC Davis stem cell researcher Paul Knoepfler has
posted a good look at the some of the misinformation that is
surfacing on the Internet about the research, including its
implications.
He said,
“Keep in mind that on day one of the
iPS cell era in the stem cell field we had a huge number of
misconceptions because we simply had so much to learn. Same is true
here.”
Jessica Cussins over at the
Berkeley-based Biopolitical Times also has a solid roundup of the
coverage of the Oregon research and the analysis of its significance.
Berkeley-based Biopolitical Times also has a solid roundup of the
coverage of the Oregon research and the analysis of its significance.
Here are links to two blog items from
the California stem cell agency on the Oregon research, including one
dealing with “cloning hysteria” and a more general look.
the California stem cell agency on the Oregon research, including one
dealing with “cloning hysteria” and a more general look.
Source:Stem Cell Therapy
Comments Off on Oregon-style Stem Cell Cloning Research Illegal in California: No Pay for Eggs in Golden State |
May 19th, 2013
Klein, StemCells, Inc., and $31,000 in Consulting Fees for Torres
By Dr. Matthew Watson
The Robert Klein-StemCells, Inc.,
affair has taken another turn with the disclosure that a vice
chairman of the California stem cell agency was paid at least $31,000
over a two-year period by Klein and also voted on behalf of Klein's
effort to win approval of a $20 million award for StemCells, Inc.
Art Torres received what he reported were
consulting fees during 2011 and 2012 from firms controlled by Klein, former chairman of
the agency. In 2012, Torres backed Klein's
efforts to override grant reviewers' rejection of the $20 million
application from the Newark, Ca., publicly traded firm.
consulting fees during 2011 and 2012 from firms controlled by Klein, former chairman of
the agency. In 2012, Torres backed Klein's
efforts to override grant reviewers' rejection of the $20 million
application from the Newark, Ca., publicly traded firm.
 |
| Art Torres, center, with Bob Klein, left, at Klein's last meeting in 2011 as chairman of the California stem cell agency. Incoming chairman Jonathan Thomas is at right. |
The 29-member board of the California
Institute for Regenerative Medicine (CIRM), as the agency is formally
known, narrowly voted 7-5 last September for the award. It was the
first time that the board has approved an application rejected twice
by its scientific reviewers. It was also the first time that Klein
has lobbied the board on behalf of a specific application since
stepping down in June 2011. He was elected chairman in 2005 as the
agency was just beginning its work and is an iconic figure to many in
the California stem cell community.
Asked for comment last week by the
California Stem Cell Report, Torres said,
California Stem Cell Report, Torres said,
"My decision to support an award
to StemCells, Inc. to explore the use of neural stem cell
transplantation to treat Alzheimer's disease was based on the merits
of the application and the hope it offers to patients who suffer from
Alzheimer's, a disease that affects millions, including Bob Klein's
late mother. I have no financial interest in StemCells, Inc. nor does
Bob Klein, and my decision to support the award has no connection
whatsoever to the work I do with Bob Klein."
Kevin McCormack, senior director for
public communications at CIRM, said that Torres' statement would be
the only comment on the matter from the agency.
public communications at CIRM, said that Torres' statement would be
the only comment on the matter from the agency.
Klein did not respond to questions,
declaring that personal issues were occupying his time.
declaring that personal issues were occupying his time.
The California Stem Cell Report's
questions to all three dealt with the propriety of Torres' employment
by both CIRM and Klein while Klein was asking the board to award a
business $20 million. The governing board has a code of conduct that
declares members should “maintain the highest standards of
integrity and professionalism.” However, it does not speak to
questions of appropriate employment by CIRM directors outside of the
agency.
questions to all three dealt with the propriety of Torres' employment
by both CIRM and Klein while Klein was asking the board to award a
business $20 million. The governing board has a code of conduct that
declares members should “maintain the highest standards of
integrity and professionalism.” However, it does not speak to
questions of appropriate employment by CIRM directors outside of the
agency.
In January 2012, Torres authored a document discussing CIRM's conflict of interest rules. He said they
are intended “to eliminate even the appearance of impropriety.”
He also referred to CIRM's policy on “incompatible activities”
for employees. It deals with activities that could “discredit”
the agency or that are “inimical” to it. However, it does not
specifically deal with the type of situation involving Torres and
Klein, who is a real estate investment banker and attorney. The policy additionally does not address cases where a
governing board member is also an employee of the agency.
are intended “to eliminate even the appearance of impropriety.”
He also referred to CIRM's policy on “incompatible activities”
for employees. It deals with activities that could “discredit”
the agency or that are “inimical” to it. However, it does not
specifically deal with the type of situation involving Torres and
Klein, who is a real estate investment banker and attorney. The policy additionally does not address cases where a
governing board member is also an employee of the agency.
Torres' economic disclosure statements,
which are required by state law, contain only broad ranges for compensation, and the amount could be significantly higher than
$31,000. Torres reported that in 2011 he was paid between $10,001 and
$100,000 by both Klein Financial Corp. and K CP Cal, which share the
same address as Klein's offices in Palo Alto. In 2012, Torres reported receiving between $10,001 and $100,000 from K CP Cal and
between $1,001 and $10,000 from Klein Ventures LLC, which also has
the same address.
which are required by state law, contain only broad ranges for compensation, and the amount could be significantly higher than
$31,000. Torres reported that in 2011 he was paid between $10,001 and
$100,000 by both Klein Financial Corp. and K CP Cal, which share the
same address as Klein's offices in Palo Alto. In 2012, Torres reported receiving between $10,001 and $100,000 from K CP Cal and
between $1,001 and $10,000 from Klein Ventures LLC, which also has
the same address.
Torres reported that the payments were
consulting fees and that the firms dealt with real estate. He did not
respond to requests for more details.
consulting fees and that the firms dealt with real estate. He did not
respond to requests for more details.
Torres earns $225,000 a year in his part-time role as one of two vice chairmen for the agency. Under the
arrangement, he works four days a week.
arrangement, he works four days a week.
Torres was chairman of the state
Democratic Party and a longtime state legislator. He was nominated
for vice chairman in 2009 by state Treasurer Bill Lockyer, among
others.
Democratic Party and a longtime state legislator. He was nominated
for vice chairman in 2009 by state Treasurer Bill Lockyer, among
others.
Last week, another financial
arrangement involving Klein surfaced in connection with the
StemCells, Inc., application. Klein gave the agency $21,000 last May,two months before he pitched the board on the StemCells, Inc.,application. The donation was not reported to the board prior to
Klein's appearances before the panel. The agency's regulations
require such gifts to be reported to the board but do not specify a
time frame. Following inquiries from the California Stem Cell Report,
the agency said it would report the donation at the agency board
meeting next week.
arrangement involving Klein surfaced in connection with the
StemCells, Inc., application. Klein gave the agency $21,000 last May,two months before he pitched the board on the StemCells, Inc.,application. The donation was not reported to the board prior to
Klein's appearances before the panel. The agency's regulations
require such gifts to be reported to the board but do not specify a
time frame. Following inquiries from the California Stem Cell Report,
the agency said it would report the donation at the agency board
meeting next week.
Klein's donation financed a trip by six
CIRM science officers to Japan for an international stem cell
conference. The agency directed the officers to give special access
to Klein. Two of the officers were heavily involved in the grant
round that included the StemCells, Inc., application, which scientific reviewers scored at 61 on a scale of 100.
CIRM science officers to Japan for an international stem cell
conference. The agency directed the officers to give special access
to Klein. Two of the officers were heavily involved in the grant
round that included the StemCells, Inc., application, which scientific reviewers scored at 61 on a scale of 100.
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/7zwWISe_LMA/klein-stemcells-inc-and-31000-in.html
Stem Cell Therapy
Comments Off on Klein, StemCells, Inc., and $31,000 in Consulting Fees for Torres |
May 19th, 2013